Adage Capital Partners’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Adage Capital Partners's SMMT Position: Q3 2026 in Review
Adage Capital Partners reduced its Summit Therapeutics (SMMT) stake by 71% in Q3 2026, selling an estimated $21M and leaving 586,607 shares worth $9.9M. The position accounts for 0.01% of the portfolio, ranked #725.
Adage Capital Partners first reported a position in SMMT in Q1 2025 and has held it in 3 quarters since. The position peaked at $29M in Q2 2026. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Adage Capital Partners held 586,607 shares of Summit Therapeutics worth $9.9M as of Q3 2026.
- Adage Capital Partners sold 1,402,984 Summit Therapeutics shares in Q3 2026, an estimated $21M.
- Summit Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q3 2026, its #725 holding.
- Adage Capital Partners first reported a position in Summit Therapeutics in Q1 2025 and has held it in 3 quarters since.
- Adage Capital Partners's Summit Therapeutics position peaked at $29M in Q2 2026.
- 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.